FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 332:1553-1559 June 8, 1995 Number 23 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article PubMed Citation

Platelets have a key role in atherosclerosis, thrombosis, and acute coronary syndromes. Therapeutic manipulation of platelet function has focused principally on the use of aspirin, which has proved effective in many clinical situations, despite its relatively weak antiplatelet action. More recently, the platelet glycoprotein IIb/IIIa receptor has been identified as the pivotal mediator of platelet aggregation, making it a logical target for control of the platelet response to vascular injury. This review summarizes the current state of knowledge of the biology of glycoprotein IIb/IIIa receptors and examines the development of agents that inhibit these receptors — a diverse group of . . . [Full Text of this Article]

Biology of Platelet Function

Platelet Adhesion and Aggregation

Structure and Function of the Glycoprotein IIb/IIIa Receptor

Development of Glycoprotein IIb/IIIa–Receptor Inhibitors

Clinical Studies of Glycoprotein IIb/IIIa–Receptor Inhibitors

Coronary Angioplasty

Unstable Angina and Myocardial Infarction

Issues That Remain to Be Addressed

Conclusions

Source Information

From the Department of Cardiology and the Joseph J. Jacobs Center for Thrombosis and Vascular Biology, Cleveland Clinic Foundation, Cleveland.

Address reprint requests to Dr. Topol at the Department of Cardiology, One Clinic Center, Cleveland Clinic Foundation, Cleveland, OH 44195.

References

This article has been cited by other articles:

• Mengistu, A. M., Rohm, K. D., Boldt, J., Mayer, J., Suttner, S. W., Piper, S. N. (2008). The Influence of Aprotinin and Tranexamic Acid on Platelet Function and Postoperative Blood Loss in Cardiac Surgery. Anesth. Analg. 107: 391-397 [Abstract] [Full Text]  
• Natarajan, A., Zaman, A. G, Marshall, S. M (2008). Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents. Diabetes and Vascular Disease Research 5: 138-144 [Abstract]  
• Rousseau, P., Tartas, M., Fromy, B., Godon, A., Custaud, M.-A., Saumet, J. L., Abraham, P. (2008). Platelet inhibition by low-dose aspirin but not by clopidogrel reduces the axon-reflex current-induced vasodilation in humans. Am. J. Physiol. Regul. Integr. Comp. Physiol. 294: R1420-R1426 [Abstract] [Full Text]  
• Tetik, S., Uras, F., Eksioglu-Demiralp, E., Turay Yardimci, K. (2008). Low-Density Lipoprotein Specifically Binds Glycoprotein IIb/IIIa: A Flow Cytometric Method for Ligand-Receptor Interaction. CLIN APPL THROMB HEMOST 14: 210-219 [Abstract]  
• Gurm, H. S., Nallamothu, B. K., Yadav, J. (2008). Safety of carotid artery stenting for symptomatic carotid artery disease: a meta-analysis. Eur Heart J 29: 113-119 [Abstract] [Full Text]  
• Hammon, J. W. (2008). Extracorporeal Circulation: The Response of Humoral and Cellular Elements of Blood to Extracorporeal Circulation. Card Surg Adult 3: 370-389 [Full Text]  
• Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E. Jr, Chavey, W. E. II, Fesmire, F. M., Hochman, J. S., Levin, T. N., Lincoff, A. M., Peterson, E. D., Theroux, P., Wenger, N. K., Wright, R. S., Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Anderson, J. L., Antman, E. M., Halperin, J. L., Hunt, S. A., Krumholz, H. M., Kushner, F. G., Lytle, B. W., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B. (2007). ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 50: e1-e157 [Full Text]  
• Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E. Jr, Chavey, W. E. II, Fesmire, F. M., Hochman, J. S., Levin, T. N., Lincoff, A. M., Peterson, E. D., Theroux, P., Wenger, N. K., Wright, R. S., Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Anderson, J. L., Antman, E. M., Halperin, J. L., Hunt, S. A., Krumholz, H. M., Kushner, F. G., Lytle, B. W., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B. (2007). ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 50: 652-726 [Full Text]  
• Ruggeri, Z. M., Mendolicchio, G. L. (2007). Adhesion Mechanisms in Platelet Function. Circ. Res. 100: 1673-1685 [Abstract] [Full Text]  
• Aronow, W. S. (2007). Use of Antiplatelet Drugs in Secondary Prevention in Older Persons With Atherothrombotic Disease. J Gerontol A Biol Sci Med Sci 62: 518-524 [Abstract] [Full Text]  
• Voss, B., McLaughlin, J. N., Holinstat, M., Zent, R., Hamm, H. E. (2007). PAR1, but Not PAR4, Activates Human Platelets through a Gi/o/Phosphoinositide-3 Kinase Signaling Axis. Mol. Pharmacol. 71: 1399-1406 [Abstract] [Full Text]  
• Deliargyris, E. N., Upadhya, B., Melton, L. G., Thompson, C., Fisher, M., Gabriel, D. A., Dehmer, G. J., Sane, D. C. (2006). Unfractionated Heparin Reduces the Anti-Platelet Effects of Abciximab but not Eptifibatide During PCI. CLIN APPL THROMB HEMOST 12: 458-464 [Abstract]  
• Freedman, J. E. (2005). Molecular Regulation of Platelet-Dependent Thrombosis. Circulation 112: 2725-2734 [Abstract] [Full Text]  
• Chen, P., Sun, C.-X., Liu, J.-N. (2005). A Novel Anti-platelet Monoclonal Antibody (3C7) Specific for the Complex of Integrin {alpha}IIb{beta}3 Inhibits Platelet Aggregation and Adhesion. J. Biol. Chem. 280: 25403-25408 [Abstract] [Full Text]  
• Liu, J., Jackson, C. W., Gruppo, R. A., Jennings, L. K., Gartner, T. K. (2005). The {beta}3 subunit of the integrin {alpha}IIb{beta}3 regulates {alpha}IIb-mediated outside-in signaling. Blood 105: 4345-4352 [Abstract] [Full Text]  
• Stratmann, B., Tschoepe, D. (2005). Pathobiology and cell interactions of platelets in diabetes. Diabetes and Vascular Disease Research 2: 16-23 [Abstract]  
• Kullo, I. J., Ballantyne, C. M. (2005). Conditional Risk Factors for Atherosclerosis. Mayo Clin Proc. 80: 219-230 [Abstract]  
• Jones, C. B, Sane, D. C, Herrington, D. M (2003). Matrix metalloproteinases: A review of their structure and role in acute coronary syndrome. Cardiovasc Res 59: 812-823 [Abstract] [Full Text]  
• Bojesen, S. E., Juul, K., Schnohr, P., Tybjaerg-Hansen, A., Nordestgaard, B.o. G. (2003). Platelet glycoprotein IIb/IIIa PlA2/PlA2 homozygosity associated with risk of ischemic cardiovascular disease and myocardial infarction in young men: The Copenhagen City Heart Study. J Am Coll Cardiol 42: 661-667 [Abstract] [Full Text]  
• Reinhart, W. H (2003). Fibrinogen - marker or mediator of vascular disease?. Vasc Med 8: 211-216 [Abstract]  
• Tabuchi, A., Yoshioka, A., Higashi, T., Shirakawa, R., Nishioka, H., Kita, T., Horiuchi, H. (2003). Direct Demonstration of Involvement of Protein Kinase C{alpha} in the Ca2+-induced Platelet Aggregation. J. Biol. Chem. 278: 26374-26379 [Abstract] [Full Text]  
• Junghans, U., Siebler, M. (2003). Cerebral Microembolism Is Blocked by Tirofiban, a Selective Nonpeptide Platelet Glycoprotein IIb/IIIa Receptor Antagonist. Circulation 107: 2717-2721 [Abstract] [Full Text]  
• Singh, M., Rosenschein, U., Ho, K. K.L., Berger, P. B., Kuntz, R., Holmes, Jr, D. R. (2003). Treatment of Saphenous Vein Bypass Grafts With Ultrasound Thrombolysis: A Randomized Study (ATLAS). Circulation 107: 2331-2336 [Abstract] [Full Text]  
• Brown, D L (2003). Deaths associated with platelet glycoprotein IIb/IIIa inhibitor treatment. Heart 89: 535-537 [Abstract] [Full Text]  
• Edmunds, L. H. Jr., Colman, R. W. (2003). Extracorporeal Circulation: Thrombosis and Bleeding. Card Surg Adult 2: 338-348 [Full Text]  
• Wang, X., Dorsam, R. T., Lauver, A., Wang, H., Barbera, F. A., Gibbs, S., Varon, D., Savion, N., Friedman, S. M., Feuerstein, G. Z. (2002). Comparative Analysis of Various Platelet Glycoprotein IIb/IIIa Antagonists on Shear-Induced Platelet Activation and Adhesion. J. Pharmacol. Exp. Ther. 303: 1114-1120 [Abstract] [Full Text]  
• Fu, L.-W., Longhurst, J. C (2002). Activated platelets contribute to stimulation of cardiac afferents during ischaemia in cats: role of 5-HT3 receptors. J. Physiol. 544: 897-912 [Abstract] [Full Text]  
• Mills, J.D., Mansfield, M.W., Grant, P.J. (2002). Elevated fibrinogen in the healthy male relatives of patients with severe, premature coronary artery disease. Eur Heart J 23: 1276-1281 [Abstract]  
• Galt, S. W., Lindemann, S., Allen, L., Medd, D. J., Falk, J. M., McIntyre, T. M., Prescott, S. M., Kraiss, L. W., Zimmerman, G. A., Weyrich, A. S. (2002). Outside-In Signals Delivered by Matrix Metalloproteinase-1 Regulate Platelet Function. Circ. Res. 90: 1093-1099 [Abstract] [Full Text]  
• Baue, A. E. (2002). It's Acronymania All Over Again: With Due Reference to YB Yogi Berra. Arch Surg 137: 486-489 [Full Text]  
• Dormandy, J.A. (2002). Antiplatelet therapy in patients with claudication: lessons from large trials. Eur Heart J Suppl 4: B55-B57 [Abstract]  
• MANOHARAN, G, ADGEY, A A J (2001). Glycoprotein IIb/IIIa inhibitors and acute coronary syndromes: summary report of the full submission to NICE, and beyond. Heart 86: 259-261 [Full Text]  
• Fintel, D. J. (2001). From bench to bedside: GP IIb-IIIa inhibitors. Neurology 57: S12-19 [Abstract] [Full Text]  
• Lincoff, A. M., Kereiakes, D. J., Mascelli, M. A., Deckelbaum, L. I., Barnathan, E. S., Patel, K. K., Frederick, B., Nakada, M. T., Topol, E. J. (2001). Abciximab Suppresses the Rise in Levels of Circulating Inflammatory Markers After Percutaneous Coronary Revascularization. Circulation 104: 163-167 [Abstract] [Full Text]  
• Kabbani, S. S., Watkins, M. W., Ashikaga, T., Terrien, E. F., Holoch, P. A., Sobel, B. E., Schneider, D. J. (2001). Platelet Reactivity Characterized Prospectively: A Determinant of Outcome 90 Days After Percutaneous Coronary Intervention. Circulation 104: 181-186 [Abstract] [Full Text]  
• O'Shea, J. C., Hafley, G. E., Greenberg, S., Hasselblad, V., Lorenz, T. J., Kitt, M. M., Strony, J., Tcheng, J. E., for the ESPRIT Investigators, (2001). Platelet Glycoprotein IIb/IIIa Integrin Blockade With Eptifibatide in Coronary Stent Intervention: The ESPRIT Trial: A Randomized Controlled Trial. JAMA 285: 2468-2473 [Abstract] [Full Text]  
• Antman, A.M., de Lemos, J.A., Braunwald, E. (2001). Epicardial flow and myocardial reperfusion following abciximab and low-dose thrombolytic therapy for acute myocardial infarction. Eur Heart J Suppl 3: A8-A13 [Abstract]  
• Akkerhuis, K M, van den Brand, M J B M, van der Zwaan, C, Peels, H O J, Suryapranata, H, van der Wieken, L R, Stibbe, J, Hoffmann, J, Baardman, T, Deckers, J W, Simoons, M L (2001). Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty. Heart 85: 444-450 [Abstract] [Full Text]  
• Cairns, J. A., Theroux, P., Lewis, H. D. Jr., Ezekowitz, M., Meade, T. W. (2001). Antithrombotic Agents in Coronary Artery Disease. Chest 119 : 228S-252S [Full Text]  
• Akkerhuis, K. M., Neuhaus, K.-L., Wilcox, R. G., Vahanian, A., Boland, J.-L., Hoffmann, J., Baardman, T., Nehmiz, G., Roth, U., Klootwijk, A. P. J., Deckers, J. W., Simoons, M. L., Fibrinogen Receptor Occupancy STudy Investigators, (2000). Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation A phase II study. Eur Heart J 21: 2042-2055 [Abstract]  
• Bhatt, D. L., Topol, E. J. (2000). Current Role of Platelet Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes. JAMA 284: 1549-1558 [Abstract] [Full Text]  
• Braunwald, E., Antman, E. M., Beasley, J. W., Califf, R. M., Cheitlin, M. D., Hochman, J. S., Jones, R. H., Kereiakes, D., Kupersmith, J., Levin, T. N., Pepine, C. J., Schaeffer, J. W., Smith, E. E. III, Steward, D. E., Theroux, P., Gibbons, R. J., Alpert, J. S., Eagle, K. A., Faxon, D. P., Fuster, V., Gardner, T. J., Gregoratos, G., Russell, R. O., Smith, S. C. Jr (2000). ACC/AHA guidelines for the management of patients with unstable angina and non-st-segment elevation myocardial infarction: A report of the american college of cardiology/ american heart association task force on practice guidelines (committee on the management of patients with unstable angina). J Am Coll Cardiol 36: 970-1062 [Full Text]  
• Jandrot-Perrus, M., Busfield, S., Lagrue, A.-H., Xiong, X., Debili, N., Chickering, T., Couedic, J.-P. L., Goodearl, A., Dussault, B., Fraser, C., Vainchenker, W., Villeval, J.-L. (2000). Cloning, characterization, and functional studies of human and mouse glycoprotein VI: a platelet-specific collagen receptor from the immunoglobulin superfamily. Blood 96: 1798-1807 [Abstract] [Full Text]  
• Harrington, R. A., Armstrong, P. W., Graffagnino, C., Van de Werf, F., Kereiakes, D. J., Sigmon, K. N., Card, T., Joseph, D. M., Samuels, R., Granett, J., Chan, R., Califf, R. M., Topol, E. J. (2000). Dose-Finding, Safety, and Tolerability Study of an Oral Platelet Glycoprotein IIb/IIIa Inhibitor, Lotrafiban, in Patients With Coronary or Cerebral Atherosclerotic Disease. Circulation 102: 728-735 [Abstract] [Full Text]  
• Levy, J. H. (2000). Platelet inhibitors and bleeding in cardiac surgical patients. Ann. Thorac. Surg. 70: S9-11 [Abstract] [Full Text]  
• Silvestry, S. C., Smith, P. K. (2000). Current status of cardiac surgery in the abciximab-treated patient. Ann. Thorac. Surg. 70: S12-19 [Abstract] [Full Text]  
• O'Neill, W. W., Serruys, P., Knudtson, M., van Es, G.-A., Timmis, G. C., van der Zwaan, C., Kleiman, J., Gong, J., Roecker, E. B., Dreiling, R., Alexander, J., Anders, R., The EXCITE Trial Investigators, (2000). Long-Term Treatment with a Platelet Glycoprotein-Receptor Antagonist after Percutaneous Coronary Revascularization. NEJM 342: 1316-1324 [Abstract] [Full Text]  
• Lincoff, A. M., Califf, R. M., Topol, E. J. (2000). Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease. J Am Coll Cardiol 35: 1103-1115 [Abstract] [Full Text]  
• Bhatt, D. L., Marso, S. P., Lincoff, A. M., Wolski, K. E., Ellis, S. G., Topol, E. J. (2000). Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol 35: 922-928 [Abstract] [Full Text]  
• Yano, M., Kojima, S., Sugi, T., Matsumoto, Y., Kuramochi, M., Yoshitomi, Y. (2000). Long-Term Follow-up of Primary Stenting with Coil Stent in Acute Myocardial Infarction. ANGIOLOGY 51: 107-114 [Abstract]  
• Yeghiazarians, Y., Braunstein, J. B., Askari, A., Stone, P. H. (2000). Unstable Angina Pectoris. NEJM 342: 101-114 [Full Text]  
• Smith, K. M., Mehta, J. L. (2000). Reviews: Glycoprotein IIb/IIIa Receptor Inhibitors in Acute Coronary Syndromes: Conquests and New Challenges. J CARDIOVASC PHARMACOL THER 5: 143-150  
• SALIDO, E., MARTÍN, B., BARRIOS, Y., LINARES, J. D., HERNÁNDEZ, D., COBOS, M., CHECA, M. D., HORTAL, L., FERNÁNDEZ, A., GARCÍA, J. J., TORRES, A. (1999). The PlA2 Polymorphism of the Platelet Glycoprotein IIIA Gene as a Risk Factor for Acute Renal Allograft Rejection. J. Am. Soc. Nephrol. 10: 2599-2605 [Abstract] [Full Text]  
• Armstrong, P. W. (1999). Unsticking platelets: the role of glycoprotein IIb/IIIa receptor blockade. CMAJ 161: 1423-1424 [Full Text]  
• Hooper, W. C., Lally, C., Austin, H., Benson, J., Dilley, A., Wenger, N. K., Whitsett, C., Rawlins, P., Evatt, B. L. (1999). The Relationship Between Polymorphisms in the Endothelial Cell Nitric Oxide Synthase Gene and the Platelet GPIIIa Gene With Myocardial Infarction and Venous Thromboembolism in African Americans. Chest 116: 880-886 [Abstract] [Full Text]  
• Mikkelsson, J., Perola, M., Laippala, P., Savolainen, V., Pajarinen, J., Lalu, K., Penttila, A., Karhunen, P. J. (1999). Glycoprotein IIIa PlA Polymorphism Associates With Progression of Coronary Artery Disease and With Myocardial Infarction in an Autopsy Series of Middle-Aged Men Who Died Suddenly. Arterioscler. Thromb. Vasc. Bio. 19: 2573-2578 [Abstract] [Full Text]  
• Ryan, T. J., Antman, E. M., Brooks, N. H., Califf, R. M., Hillis, L. D., Hiratzka, L. F., Rapaport, E., Riegel, B., Russell, R. O., Smith, E. E. III, Weaver, W. D., Gibbons, R. J., Alpert, J. S., Eagle, K. A., Gardner, T. J., Garson, A. Jr, Gregoratos, G., Russell, R. O., Ryan, T. J., Smith, S. C. Jr (1999). 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 34: 890-911 [Full Text]  
• Scarborough, R. M., Kleiman, N. S., Phillips, D. R. (1999). Platelet Glycoprotein IIb/IIIa Antagonists : What Are the Relevant Issues Concerning Their Pharmacology and Clinical Use?. Circulation 100: 437-444 [Abstract] [Full Text]  
• Ruggeri, Z. M., Dent, J. A., Saldivar, E. (1999). Contribution of Distinct Adhesive Interactions to Platelet Aggregation in Flowing Blood. Blood 94: 172-178 [Abstract] [Full Text]  
• Tselepis, A. D., Goudevenos, J. A., Tambaki, A. P., Michalis, L., Stroumbis, C. S., Tsoukatos, D. C., Elisaf, M., Sideris, D. A. (1999). Platelet aggregatory response to platelet activating factor (PAF), ex vivo, and PAF-acetylhydrolase activity in patients with unstable angina: effect of c7E3 Fab (abciximab) therapy. Cardiovasc Res 43: 183-191 [Abstract] [Full Text]  
• Vorchheimer, D. A., Badimon, J. J., Fuster, V. (1999). Platelet Glycoprotein IIb/IIIa Receptor Antagonists in Cardiovascular Disease. JAMA 281: 1407-1414 [Abstract] [Full Text]  
• Ma, J., Hennekens, C. H., Ridker, P. M., Stampfer, M. J. (1999). A prospective study of fibrinogen and risk of myocardial infarction in the physicians' health study. J Am Coll Cardiol 33: 1347-1352 [Abstract] [Full Text]  
• Eto, K., Isshiki, T., Yamamoto, H., Takeshita, S., Ochiai, M., Yokoyama, N., Yoshimoto, R., Ikeda, Y., Sato, T. (1999). AJvW-2, an Anti-vWF Monoclonal Antibody, Inhibits Enhanced Platelet Aggregation Induced by High Shear Stress in Platelet-Rich Plasma From Patients With Acute Coronary Syndromes. Arterioscler. Thromb. Vasc. Bio. 19: 877-882 [Abstract] [Full Text]  
• Bednar, M. M., Gross, C. E. (1999). Antiplatelet Therapy in Acute Cerebral Ischemia. Stroke 30: 887-893 [Abstract] [Full Text]  
• Anderson, J. L., King, G. J., Bair, T. L., Elmer, S. P., Muhlestein, J. B., Habashi, J., Carlquist, J. F. (1999). Associations between a polymorphism in the gene encoding glycoprotein IIIa and myocardial infarction or coronary artery disease. J Am Coll Cardiol 33: 727-733 [Abstract] [Full Text]  
• Folts, J. D., Schafer, A. I., Loscalzo, J., Willerson, J. T., Muller, J. E. (1999). A perspective on the potential problems with aspirin as an antithrombotic agent: a comparison of studies in an animal model with clinical trials. J Am Coll Cardiol 33: 295-303 [Abstract] [Full Text]  
• Bates, S. M., Weitz, J. I. (1999). Prevention of activation of blood coagulation during acute coronary ischemic syndromes: beyond aspirin and heparin. Cardiovasc Res 41: 418-432 [Abstract] [Full Text]  
• Gawaz, M., Neumann, F.-J., Schomig, A. (1999). Evaluation of Platelet Membrane Glycoproteins in Coronary Artery Disease : Consequences for Diagnosis and Therapy. Circulation 99 : e1-e11 [Full Text]  
• Kong, D. F., Califf, R. M., Miller, D. P., Moliterno, D. J., White, H. D., Harrington, R. A., Tcheng, J. E., Lincoff, A. M., Hasselblad, V., Topol, E. J. (1998). Clinical Outcomes of Therapeutic Agents That Block the Platelet Glycoprotein IIb/IIIa Integrin in Ischemic Heart Disease. Circulation 98: 2829-2835 [Abstract] [Full Text]  
• Madan, M., Berkowitz, S. D., Tcheng, J. E. (1998). Glycoprotein IIb/IIIa Integrin Blockade. Circulation 98: 2629-2635 [Full Text]  
• The Paradigm Investigators, (1998). Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) Trial. J Am Coll Cardiol 32: 2003-2010 [Abstract] [Full Text]  
• Shiraga, M., Tomiyama, Y., Honda, S., Suzuki, H., Kosugi, S., Tadokoro, S., Kanakura, Y., Tanoue, K., Kurata, Y., Matsuzawa, Y. (1998). Involvement of Na+/Ca2+ Exchanger in Inside-Out Signaling Through the Platelet Integrin alpha IIbbeta 3. Blood 92: 3710-3720 [Abstract] [Full Text]  
• Topol, E. J., Serruys, P. W. (1998). Frontiers in Interventional Cardiology. Circulation 98: 1802-1820 [Full Text]  
• The PURSUIT Trial Investigators, (1998). Inhibition of Platelet Glycoprotein IIb/IIIa with Eptifibatide in Patients with Acute Coronary Syndromes. NEJM 339: 436-443 [Abstract] [Full Text]  
• Musselman, D. L., Evans, D. L., Nemeroff, C. B. (1998). The Relationship of Depression to Cardiovascular Disease: Epidemiology, Biology, and Treatment. Arch Gen Psychiatry 55: 580-592 [Abstract] [Full Text]  
• Rebello, S. S., Huang, J., Saito, K., Lucchesi, B. R. (1998). In Vivo Efficacy of SM-20302, a GP IIb/IIIa Receptor Antagonist, Correlates With Ex Vivo Platelet Inhibition in Heparinized Blood but Not in Citrated Blood. Arterioscler. Thromb. Vasc. Bio. 18: 954-960 [Abstract] [Full Text]  
• The Platelet Receptor Inhibition in Ischemic Syndr, (1998). Inhibition of the Platelet Glycoprotein IIb/IIIa Receptor with Tirofiban in Unstable Angina and Non-Q-Wave Myocardial Infarction. NEJM 338: 1488-1497 [Abstract] [Full Text]  
• Hillis, G S, Flapan, A D (1998). Cell adhesion molecules in cardiovascular disease: a clinical perspective. Heart 79: 429-431 [Full Text]  
• Shattil, S. J., Kashiwagi, H., Pampori, N. (1998). Integrin Signaling: The Platelet Paradigm. Blood 91: 2645-2657 [Full Text]  
• Teo, K. K (1998). Recent advances: Cardiology. BMJ 316: 911-915 [Full Text]  
• Wagner, K. R., Giles, W. H., Johnson, C. J., Ou, C.-Y., Bray, P. F., Goldschmidt-Clermont, P. J., Croft, J. B., Brown, V. K., Stern, B. J., Feeser, B. R., Buchholz, D. W., Earley, C. J., Macko, R. F., McCarter, R. J., Sloan, M. A., Stolley, P. D., Wityk, R. J., Wozniak, M. A., Price, T. R., Kittner, S. J. (1998). Platelet Glycoprotein Receptor IIIa Polymorphism P1A2 and Ischemic Stroke Risk : The Stroke Prevention in Young Women Study. Stroke 29: 581-585 [Abstract] [Full Text]  
• Vorchheimer, D. A., Fuster, V. (1998). Oral Platelet Glycoprotein IIb/IIIa Receptor Antagonists: The Present Challenge Is Safety. Circulation 97: 312-314 [Full Text]  
• Conrad, M. E., Umbreit, J. N., Moore, E. G., Fischman, D. L., Savage, M. P. (1998). Integrin {beta}3 Blockade With Abciximab and Protection From Myocardial Ischemic Events. JAMA 279: 195-196 [Full Text]  
• Ballow, M., Nelson, R. (1997). Immunopharmacology: Immunomodulation and Immunotherapy. JAMA 278: 2008-2017 [Abstract]  
• Hamm, C. W., Goldmann, B. U., Heeschen, C., Kreymann, G., Berger, J., Meinertz, T. (1997). Emergency Room Triage of Patients with Acute Chest Pain by Means of Rapid Testing for Cardiac Troponin T or Troponin I. NEJM 337: 1648-1653 [Abstract] [Full Text]  
• Spiess, B. D. (1997). Endothelial Cell-Blood Interface Actions and the Procoagulant Response. SEMIN CARDIOTHORAC VASC ANESTH 1: 288-294 [Abstract]  
• Byrne, A., Moran, N., Maher, M., Walsh, N., Crean, P., Fitzgerald, D. J. (1997). Continued Thromboxane A2 Formation Despite Administration of a Platelet Glycoprotein IIb/IIIa Antagonist in Patients Undergoing Coronary Angioplasty. Arterioscler. Thromb. Vasc. Bio. 17: 3224-3229 [Abstract] [Full Text]  
• Anderson, H. V., Jordan, R. E., Weisman, H. F. (1997). Concept and Clinical Application of Platelet Glycoprotein IIb/IIIa Inhibition with Abciximab (c7E3 Fab; ReoPro) for the Prevention of Acute Ischemic Syndromes. CLIN APPL THROMB HEMOST 3: 256-266 [Abstract]  
• Phillips, D. R., Teng, W., Arfsten, A., Nannizzi-Alaimo, L., White, M. M., Longhurst, C., Shattil, S. J., Randolph, A., Jakubowski, J. A., Jennings, L. K., Scarborough, R. M. (1997). Effect of Ca2+ on GP IIb-IIIa Interactions With Integrilin : Enhanced GP IIb-IIIa Binding and Inhibition of Platelet Aggregation by Reductions in the Concentration of Ionized Calcium in Plasma Anticoagulated With Citrate. Circulation 96: 1488-1494 [Abstract] [Full Text]  
• Muller, T. H., Weisenberger, H., Brickl, R., Narjes, H., Himmelsbach, F., Krause, J. (1997). Profound and Sustained Inhibition of Platelet Aggregation by Fradafiban, a Nonpeptide Platelet Glycoprotein IIb/IIIa Antagonist, and Its Orally Active Prodrug, Lefradafiban, in Men. Circulation 96: 1130-1138 [Abstract] [Full Text]  
• Topol, E. J., Ferguson, J. J., Weisman, H. F., Tcheng, J. E., Ellis, S. G., Kleiman, N. S., Ivanhoe, R. J., Wang, A. L., Miller, D. P., Anderson, K. M., Califf, R. M. (1997). Long-term Protection From Myocardial Ischemic Events in a Randomized Trial of Brief Integrin {beta}3 Blockade With Percutaneous Coronary Intervention. JAMA 278: 479-484 [Abstract]  
• Simpfendorfer, C., Kottke-Marchant, K., Lowrie, M., Anders, R. J., Burns, D. M., Miller, D. P., Cove, C. S., DeFranco, A. C., Ellis, S. G., Moliterno, D. J., Raymond, R. E., Sutton, J. M., Topol, E. J. (1997). First Chronic Platelet Glycoprotein IIb/IIIa Integrin Blockade : A Randomized, Placebo-Controlled Pilot Study of Xemilofiban in Unstable Angina With Percutaneous Coronary Interventions. Circulation 96: 76-81 [Abstract] [Full Text]  
• Bennett, J. S., Chan, C., Vilaire, G., Mousa, S. A., DeGrado, W. F. (1997). Agonist-activated alpha vbeta 3 on Platelets and Lymphocytes Binds to the Matrix Protein Osteopontin. J. Biol. Chem. 272: 8137-8140 [Abstract] [Full Text]  
• Baim, D. S., Carrozza, J. P. Jr (1997). Stent Thrombosis: Closing in on the Best Preventive Treatment. Circulation 95: 1098-1100 [Full Text]  
• Simon, D. I., Xu, H., Ortlepp, S., Rogers, C., Rao, N. K. (1997). 7E3 Monoclonal Antibody Directed Against the Platelet Glycoprotein IIb/IIIa Cross-reacts With the Leukocyte Integrin Mac-1 and Blocks Adhesion to Fibrinogen and ICAM-1. Arterioscler. Thromb. Vasc. Bio. 17: 528-535 [Abstract] [Full Text]  
• Samani, N. J., Lodwick, D. (1997). Glycoprotein IIIa polymorphism and risk of myocardial infarction. Cardiovasc Res 33: 693-697 [Abstract]  
• Coller, B. S., Lang, D., Scudder, L. E. (1997). Rapid and Simple Platelet Function Assay to Assess Glycoprotein IIb/IIIa Receptor Blockade. Circulation 95: 860-867 [Abstract] [Full Text]